Centogene N.V. Common Shares - CNTG STOCK NEWS

Centogene (Nasdaq: CNTG) reported Q3 2021 revenues of €30.2 million, down 17% from €36.3 million in Q3 2020. The Diagnostics segment saw a 43% revenue increase to €7.3 million, while Pharma revenues fell 28% to €2.7 million. COVID-19 testing revenues decreased to €20.2 million. The company is restructuring to phase out COVID-19 testing and plans to cut costs by up to €15 million annually. Cash reserves declined to €25.7 million. Centogene is optimistic about future growth in its Core Business, expecting 30-40% overall revenue growth for FY2021.

Centogene N.V. (Nasdaq: CNTG) announced it will release its financial results for Q3 2021 on November 24, 2021, at 2 p.m. CET / 8 a.m. ET. A conference call and webcast will follow to discuss these results. Participants can register in advance to receive dial-in numbers and passcodes. The company specializes in rare diseases, utilizing a unique platform with over 3.9 billion data points from 600,000 patients globally. Centogene aims to enhance diagnosis and treatment through extensive research and collaboration with over 30 pharmaceutical partners.

Centogene has expanded its partnership with Agios Pharmaceuticals to provide genetic testing and clinical trial support for pivotal studies in thalassemia and sickle cell disease. This three-year fee-for-service agreement enhances access to genetic testing for patients globally, utilizing Centogene's proprietary CentoCard® for analysis. The collaboration aims to improve understanding of these rare diseases and advance Agios' PK activator therapy, addressing unmet needs in treatment options. Centogene's extensive rare disease Bio/Databank supports this initiative.

Centogene N.V. (Nasdaq: CNTG) has announced the enrollment of the first patient in the EFRONT Study, focusing on frontotemporal dementia (FTD). This observational study aims to assess the prevalence of genetic mutations in over 3,000 FTD patients across seven countries, leveraging Centogene's extensive Bio/Databank. Currently, there are no FDA-approved treatments for FTD, which affects many under 65. Patients with the progranulin gene mutation may join Alector’s Phase 3 INFRONT-3 trial for a potential new treatment. This initiative aligns with Centogene’s goal to address 100 rare diseases in the next decade.

Centogene (Nasdaq: CNTG) and Twist Bioscience (Nasdaq: TWST) announced a collaboration to develop custom assay kits for diagnosing rare diseases. This partnership aims to enhance genetic testing accessibility and increase understanding of rare conditions. By combining Centogene's extensive database, which includes over 3.9 billion data points and insights from 600,000 patients, with Twist's advanced DNA synthesis technology, the collaboration seeks to improve the precision of rare disease diagnostics and potentially lead to novel therapeutic discoveries. Financial terms of the agreement remain undisclosed.

Twist Bioscience Corporation (TWST) and Centogene N.V. (CNTG) have partnered to develop custom assay kits targeting the diagnosis of rare diseases. This collaboration aims to enhance genetic testing accessibility for patients, ultimately improving understanding and treatment of rare conditions. Although no financial details were disclosed, the partnership seeks to utilize Centogene's extensive Bio/Databank and Twist's DNA synthesis technologies. The initiative is part of Centogene's goal to drive insights and potentially cure up to 100 rare diseases within the next decade.

Centogene (Nasdaq: CNTG) announced a major breakthrough in treating structural birth defects in a recent global genetic study published in the New England Journal of Medicine. Utilizing data from over 20,000 families, researchers identified genetic variations in the WLS gene linked to these defects. A pharmacologic Wnt agonist was able to restore embryonic development in preclinical models. This study marks a significant step toward developing targeted therapies for 4 million infants affected by birth defects annually, highlighting Centogene's commitment to curing 100 rare diseases within the next decade.

Centogene N.V. (Nasdaq: CNTG) reported strong Q2 2021 results, achieving revenues of €51.9 million, a 434% increase from €9.7 million in Q2 2020. The firm highlighted a 25% rise in revenues from its core Pharma and Diagnostics segments, with Clinical Diagnostics growing 82% to €6.7 million. Significant COVID-19 testing revenues of €42.3 million contributed to overall earnings. However, Pharma revenues declined to €2.8 million. With a focus on rare diseases, Centogene aims to enable cures for 100 rare diseases in the next decade, driven by the growth of its Bio/Databank and new executive appointments.

Centogene N.V. (Nasdaq: CNTG) announced that it will release its financial results for the quarter ending June 30, 2021, on September 7, 2021. A conference call and webcast will follow at 2 p.m. CEST / 8 a.m. EDT to discuss these results. Centogene focuses on rare diseases, utilizing a vast global data platform comprising over 3.9 billion data points from approximately 600,000 patients across 120 countries to enhance diagnosis and treatment. The firm collaborates with over 30 pharmaceutical partners to drive orphan drug development.